beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.

Nicotinic acid is one of the most effective agents for both lowering triglycerides and raising HDL. However, the side effect of cutaneous flushing severely limits patient compliance. As nicotinic acid stimulates the GPCR GPR109A and Gi/Go proteins, here we dissected the roles of G proteins and the adaptor proteins, beta-arrestins, in nicotinic acid-induced signaling and physiological responses. In a human cell line-based signaling assay, nicotinic acid stimulation led to pertussis toxin-sensitive lowering of cAMP, recruitment of beta-arrestins to the cell membrane, an activating conformational change in beta-arrestin, and beta-arrestin-dependent signaling to ERK MAPK. In addition, we found that nicotinic acid promoted the binding of beta-arrestin1 to activated cytosolic phospholipase A2 as well as beta-arrestin1-dependent activation of cytosolic phospholipase A2 and release of arachidonate, the precursor of prostaglandin D2 and the vasodilator responsible for the flushing response. Moreover, beta-arrestin1-null mice displayed reduced cutaneous flushing in response to nicotinic acid, although the improvement in serum free fatty acid levels was similar to that observed in wild-type mice. These data suggest that the adverse side effect of cutaneous flushing is mediated by beta-arrestin1, but lowering of serum free fatty acid levels is not. Furthermore, G protein-biased ligands that activate GPR109A in a beta-arrestin-independent fashion may represent an improved therapeutic option for the treatment of dyslipidemia.

[1]  R. Andersson,et al.  Studies on the mechanism of flush induced by nicotinic acid. , 2009, Acta pharmacologica et toxicologica.

[2]  D. Connolly,et al.  Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. , 2008, Journal of clinical lipidology.

[3]  D. Connolly,et al.  3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. , 2008, Journal of medicinal chemistry.

[4]  Robert J. Lefkowitz,et al.  β-Arrestin-biased Agonism at the β2-Adrenergic Receptor* , 2008, Journal of Biological Chemistry.

[5]  Necmettin Yildirim,et al.  β2-Adrenergic Receptor Signaling and Desensitization Elucidated by Quantitative Modeling of Real Time cAMP Dynamics* , 2008, Journal of Biological Chemistry.

[6]  T. Kenakin.  Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship? , 2007, Molecular Pharmacology.

[7]  Robert J. Lefkowitz,et al.  A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling , 2007, Proceedings of the National Academy of Sciences.

[8]  J. Guyton.  Niacin in cardiovascular prevention: mechanisms, efficacy, and safety , 2007, Current opinion in lipidology.

[9]  Daniel B. McClatchy,et al.  Functional specialization of β-arrestin interactions revealed by proteomic analysis , 2007, Proceedings of the National Academy of Sciences.

[10]  D. Connolly,et al.  Nicotinic Acid Receptor Agonists Differentially Activate Downstream Effectors* , 2007, Journal of Biological Chemistry.

[11]  E. Lai,et al.  Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1 , 2007, Clinical pharmacology and therapeutics.

[12]  Paul Y. Liu,et al.  Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. , 2007, Atherosclerosis.

[13]  R. Lefkowitz,et al.  β-Arrestins and Cell Signaling , 2007 .

[14]  R. Lefkowitz,et al.  New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. , 2006, Molecular cell.

[15]  Clare L. Bennett,et al.  Nicotinic Acid-Induced Flushing Is Mediated by Activation of Epidermal Langerhans Cells , 2006, Molecular Pharmacology.

[16]  Robert J. Lefkowitz,et al.  G-protein-coupled Receptor Kinase Specificity for β-Arrestin Recruitment to the β2-Adrenergic Receptor Revealed by Fluorescence Resonance Energy Transfer* , 2006, Journal of Biological Chemistry.

[17]  R. Lefkowitz,et al.  Distinct β-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation* , 2006, Journal of Biological Chemistry.

[18]  N. Pike.  Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. , 2005, The Journal of clinical investigation.

[19]  Z. Benyó,et al.  GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. , 2005, The Journal of clinical investigation.

[20]  L. Svetkey,et al.  The Study of the Effects of Diet on Metabolism and Nutrition (STEDMAN) weight loss project: Rationale and design. , 2005, Contemporary clinical trials.

[21]  L. Bohn,et al.  Morphine Side Effects in β-Arrestin 2 Knockout Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[22]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[23]  Pascale G. Charest,et al.  Monitoring agonist‐promoted conformational changes of β‐arrestin in living cells by intramolecular BRET , 2005, EMBO reports.

[24]  Xiaodong Cheng,et al.  Fluorescent indicators of cAMP and Epac activation reveal differential dynamics of cAMP signaling within discrete subcellular compartments. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  T. Kohout,et al.  Differential Desensitization, Receptor Phosphorylation, β-Arrestin Recruitment, and ERK1/2 Activation by the Two Endogenous Ligands for the CC Chemokine Receptor 7* , 2004, Journal of Biological Chemistry.

[26]  L. Levine.  Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, non-genomic mechanism , 2003, BMC Cancer.

[27]  L. Hunyady,et al.  Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  V. Kamanna,et al.  Niacin and cholesterol: role in cardiovascular disease (review). , 2003, The Journal of nutritional biochemistry.

[29]  S. Dowell,et al.  Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid* , 2003, The Journal of Biological Chemistry.

[30]  R. Lefkowitz,et al.  Desensitization, internalization, and signaling functions of β-arrestins demonstrated by RNA interference , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Tunaru,et al.  PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect , 2003, Nature Medicine.

[32]  M. Caron,et al.  Differential Mechanisms of Morphine Antinociceptive Tolerance Revealed in βArrestin-2 Knock-Out Mice , 2002, The Journal of Neuroscience.

[33]  S. Pizzo,et al.  Regulation of Cytosolic Phospholipase A2 Activity in Macrophages Stimulated with Receptor-recognized Forms of α2-Macroglobulin , 2002, The Journal of Biological Chemistry.

[34]  T. Sakai,et al.  Niacin, but Not Gemfibrozil, Selectively Increases LP-AI, a Cardioprotective Subfraction of HDL, in Patients With Low HDL Cholesterol , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[35]  Marc G. Caron,et al.  μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence , 2000, Nature.

[36]  S. Pizzo,et al.  Cytosolic Phospholipase A2 Activity Associated with Nuclei Is Not Inhibited by Arachidonyl Trifluoromethyl Ketone in Macrophages Stimulated with Receptor-Recognized Forms of α2-Macroglobulin , 2000 .

[37]  Yue Sun,et al.  β-Arrestin Differentially Regulates the Chemokine Receptor CXCR4-mediated Signaling and Receptor Internalization, and This Implicates Multiple Interaction Sites between β-Arrestin and CXCR4* , 2000, The Journal of Biological Chemistry.

[38]  R. Gainetdinov,et al.  Enhanced morphine analgesia in mice lacking beta-arrestin 2. , 1999, Science.

[39]  V. Kamanna,et al.  Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[40]  R. Lefkowitz,et al.  Clathrin-mediated Endocytosis of the β-Adrenergic Receptor Is Regulated by Phosphorylation/Dephosphorylation of β-Arrestin1* , 1997, The Journal of Biological Chemistry.

[41]  V. Kamanna,et al.  Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[42]  Roger J. Davis,et al.  cPLA2 is phosphorylated and activated by MAP kinase , 1993, Cell.

[43]  C. Aoki,et al.  Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. , 1992, The Journal of biological chemistry.

[44]  J. Morrow,et al.  Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. , 1992, The Journal of investigative dermatology.

[45]  J. Stamler,et al.  Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.

[46]  K. Jakobs,et al.  Islet‐activating protein discriminates the antilipolytic mechanism of insulin from that of other antilipolytic compounds , 1983, FEBS letters.

[47]  L. Kaijser,et al.  Prostaglandins contribute to the vasodilation induced by nicotinic acid. , 1979, Prostaglandins.

[48]  J. Benovic,et al.  The role of receptor kinases and arrestins in G protein-coupled receptor regulation. , 1998, Annual review of pharmacology and toxicology.